Researchers have uncovered a new way to attack lymphoma by targeting a non-catalytic region of a key regulatory enzyme, rather than its traditional active site. Researchers at VCU Massey Comprehensive ...

Researchers have determined that type II innate lymphoid cells (ILC2s), a type of immune cell, can change its characteristics and functions after a cancer patient receives stem cells from a donor, ...

What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease, but a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...

New research challenges the status quo that cancer treatments are responsible for accelerating the aging process, indicating that cancer itself also plays a role. A team of researchers from Moffitt ...

Nodular sclerosis Hodgkin lymphoma is the most common subtype. It often starts in lymph nodes in the chest or neck and is ...

How Does Columvi Work for DLBCL and LBCL? Columvi is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on ...

“Allogeneic transplants can be very effective, and potentially lifesaving, but not all immune cells given to a recipient are reproduced from donor cells,” said Jonathan Serody, MD. “Innate type 2 ...